Singapore - engleză - HSA (Health Sciences Authority)

abbvie pte. ltd. - adalimumab - injection - adalimumab 40mg/0.8ml

Singapore - engleză - HSA (Health Sciences Authority)

abbvie pte. ltd. - adalimumab - injection, solution - adalimumab 80.0mg/0.8ml

Singapore - engleză - HSA (Health Sciences Authority)

abbvie pte. ltd. - adalimumab - injection, solution - adalimumab 80.0mg/0.8ml

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - adalimumab -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - adalimumab -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - adalimumab -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - adalimumab -

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - adalimumab -

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 40 mg/0.4ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - uveitis humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 20 mg/0.2ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.